Effectiveness of Nurse-coordinated Follow-up Program in Primary Care for People at Risk for T2DM

May 23, 2023 updated by: University of Akureyri

Nurse-coordinated Follow-up Program in Primary Care: a Mixed-method Complex Intervention Feasibility and RCT Pilot Trial Among People at Risk for T2DM.

Previous Icelandic studies regarding prevalence of diabetes have mostly used data from the capital area. Information on the proportion of people at risk at developing T2DM or having undiagnosed T2DM among people living in rural Northern Iceland is unknown. Clinical guidelines recommend that patients with prediabetes (diabetes warning signs) should be referred to a counselling program. The study will evaluate effectiveness of nurse-coordinated Guided Self-Determination (GSD) follow up program toward health promotion, for people at risk of T2DM.

Study Overview

Detailed Description

Prevalence of type 2 Diabetes Mellitus (T2DM) a major health problem is rising. This metabolic disease characterized by the inability to effectively metabolize glucose, and often also a silent and sneaky onset. A lag is often found between diagnose and onset of the disease. Diabetes related complications are expensive for the society, and reduce quality of life for the individual.

Around one out of three with T2DM in an Icelandic study were unaware of their T2DM when fasting blood glucose was measured. In the U.S.A., the average interval between onset of the disease and diagnose is seven years, and the authors claimed that 30% of people with T2DM are undiagnosed, with increased risk for chronic diabetes complications higher Cardiovascular risk factors (CVR), and higher premature death for people with early onset of T2DM compared to late onset of T2DM.

Research have shown 1.83-fold higher risk of CVD for those with prediabetes and 2.26-fold higher risk for individuals with undiagnosed diabetes compared to individuals with normal HbA1c. These results highlight the pivotal need to prevent development of diabetes, as there is an association between increased obesity and increased prevalence of T2DM as Type 2 diabetes (T2DM) is also found to be a major risk factor for cardiovascular diseases.

Icelandic people and especially men are becoming more overweight. From the years 1968-2012, body mass index (BMI) increased by 11%, from 25.8 kg/m2 to 28.7 kg/m2 for men between 50-69 years. In women 50-69 years, the BMI increased from 25.2 kg/m2 to 27.2 kg/m2, or 8%. These results highlight the pivotal need to prevent development of diabetes in Iceland, as there is an association between increased obesity and increased prevalence of type 2 Diabetes Mellitus (T2DM).

A Guided Self-Determination (GSD) is based on a strong theoretical value and is a well establish nurse-led interventional method for people diagnosed with T2DM and other diseases. To our knowledge this is the first time that GSD is used in Iceland. Nurses working in primary care, at The Health Care Institution of North Iceland (HSN), in Akureyri, Husavik and Sauðarkrokur, will offer the GSD intervention. Before the intervention the nurses will receive teaching and consultation from an experienced GSD diabetic nurse. During their use of the GSD method they will have counseling from the experienced GSD nurse and the PhD student. A systematic review claimed, that multi-professional interventions are more effective in improving diabetes care compared to single professional interventions.

A recent Cochrane review using data from 18 trials, investigated the impact of nurses working as substitutes for primary care doctors. The results demonstrate that using the capacity and skills of nurses to deliver primary healthcare services leads to similar or better patient health and higher patient satisfaction. As such, this might be an important strategy to improve access, efficiency, and quality of care, and at the same time strengthen health promotion aspects of care and management of chronic diseases and increase teamwork in primary care.

This study is a part of doctoral student study. This PhD project is collaboration between University of Akureyri, Iceland (UNAK), Western Norway University of Applied Sciences (HVL) and the Health Care Institution of North Iceland (HSN). HVL has a considerably experience in researching diabetes through the Diabetes Research Group for BEST Practice (DiaBEST). The research group DiaBEST consist of researchers from Bergen University Collage, the University of Bergen and the University of Stavanger. The projects contribute to increase knowledge about and implementation of evidence-based practice within primary care.

Study Type

Interventional

Enrollment (Actual)

81

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Akureyri, Iceland, 600
        • University of Akureyri

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria two of three:

  • BMI ≥ 30 kg/m2,
  • score ≥ 9 on FINDRISC,
  • HbA1c level ≥ 42 mmol/mol.
  • Non-blood-glucose-lowering medical treated T2DM.

Exclusion Criteria:

  • People diagnosed with Diabetes at strart-point.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention group
Those receiving nurse-lead Guided Self Determination (GSD) for one to three times over six months starting four to six months after recruitment and first measurement.
Nurse lead intervention in primary care
Other Names:
  • GSD
No Intervention: Control group
Those not receiving nurse-lead Guided Self Determination (GSD) for one to three times over six months starting four to six months after recruitment and first measurement.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cardiovascular Risk Factors changes up to one year after an intervention
Time Frame: 0- 6 months and 1 year
Changes for each participant from Baseline to endpoint on CVR factors, changes of risk measured in percentages (%) compared to normal risk in the Icelandic population from beginning to end of intervention. Using the Icelandic cardiovascular risk factor calculator.
0- 6 months and 1 year
Measurements behind the Icelandic heart association risk calculator
Time Frame: 0- 6 months and 1 year

Changes from baseline to endpoint:

  • Weight and height (will be combined to report BMI in kg/m^2)
  • Systolic blood pressure: In mm hg
  • Cholesterol: in mmol/L
  • HDL-Cholesterol: in mmol/L
  • Triglycerides measurements: in mmol/L,
  • Regular physical activity: yes/no
  • Smoking: never, stopped, 1/2 pack or less a day, 1/2 to 1 pack a day, 1 pack or more
  • Do you have diabetes: yes/no,
  • Do gender parents, brothers or sisters of same parents, have cardiovascular diseases : Yes/No
0- 6 months and 1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in HbA1c level
Time Frame: 0- 6 months and 1 year
Changes in HbA1c mmol/L, (normal less than 42 mmol/mol, prediabetes 42-48 mmol/mol, diabetes over 48 mmol/mol)
0- 6 months and 1 year
FINDRISC risk score "Diabetes Risk Score questionnaire"
Time Frame: 0- 6 months and 1 year
Changes from beginning to end of intervention between groups score reported on a scale from 0 - 26, (normal under 9, increased risk 9 and over)
0- 6 months and 1 year
WHO-5 Quality of Life (QoL) questionnaire
Time Frame: 0- 6 months and 1 year

Changes within and between groups from baseline to endpoint. Well-being index. The WHO-5 consists of five statements, which respondents rate according to the scale below (in relation to the past two weeks).

marking x on 5 = All of the time marking x on 4 = Most of the time marking x on 3 = More than half of the time marking x on 2 = Less than half of the time marking x on 1 = Some of the time marking x on 0 = At no time The total raw score, ranging from 0 to 25, is multiplied by 4 to give the final score, with 0 representing the worst imaginable well-being and 100 representing the best imaginable well-being.

0- 6 months and 1 year
EQ-5D-5L Questionnaire of self rated health.
Time Frame: 0- 6 months and 1 year

Changes from beginning to end of intervention within and between groups scoring from one to five at each of the five dimension 3125 definition of health state, Higher score worse outcome: Mobility dimension; Self-care dimension; Usual activities dimension; Pain/discomfort dimension; Anxiety/depression dimension.

Respondents self-rate their level of severity for each dimension using five-levels:

1 = no problems, 2 = slight problems, 3 = moderate problems, 4 = severe problems 5 = unable to do/having extreme problems.

Visual analogue scale; mark health status on the day of the interview on a 20 cm vertical scale with end points of 0 and 100. At the both ends of the scale that the bottom rate (0) corresponds to " the worst health you can imagine", and the highest rate (100) "the best health you can imagine". higher score better outcome

0- 6 months and 1 year
Health Literacy (HL) questionnaire Icelandic version: HLS-EU-Q16IS.
Time Frame: 0- 6 months and 1 year

Changes from beginning to end of intervention within and between groups 16 questions regarding health literacy. The Icelandic version asking the person from on the scale from; "very difficult", "fairly difficult", "fairly easy", "very easy",

fairly easy and very easy are united into "easy" (scored with 1) very difficult, fairly difficult are united into "difficult" (scored with 0). score can range from 0 (low/no Health Literacy) to 16 (high Health Literacy)

(Results will be grouped into two groups: less than 13 and over 13 points according to prior research results in Iceland)

0- 6 months and 1 year
Hip-to-Waist ratio
Time Frame: 0- 6 months and 1 year
Changes from beginning to end of intervention in both groups Hip-to-Waist ratio measurement: cm/cm, increased risk if ratio over 1.0
0- 6 months and 1 year

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in fastening glucose from start point to endpoint in both groups
Time Frame: 0- 6 months and 1 year
Two hours fasting blood glucose level (2HFG): mmol/L,
0- 6 months and 1 year
LDL cholesterol changes from start point to endpoint in both groups
Time Frame: 0- 6 months and 1 year
* LDL-Cholesterol:measured in mmol/L
0- 6 months and 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Arun K Sigurdardottir, PhD, University of Akureyri

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2021

Primary Completion (Actual)

January 19, 2023

Study Completion (Actual)

January 19, 2023

Study Registration Dates

First Submitted

December 1, 2020

First Submitted That Met QC Criteria

December 23, 2020

First Posted (Actual)

December 30, 2020

Study Record Updates

Last Update Posted (Actual)

May 24, 2023

Last Update Submitted That Met QC Criteria

May 23, 2023

Last Verified

May 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Risk Factor

Clinical Trials on Guided Self Determination

Subscribe